Search

Several cases of fatal enterocolitis have been described in association with the use of docetaxel (DTX), and this increase in adverse events has been concomitant with a change in formulation. Indeed in 2010, a new DTX-based presentation has been introduced in the form of a single ready-to-use vial by Sanofi-Aventis, presentation also used for generics. In this study, different available formulations were compared (Sanofi 2 vials, Sanofi 1 vial, Accord Healthcare, Kabi, Hospira) in terms of composition compliance with control specifications and simulated micelle behaviour to try to determine what could be the potential causes of this problem. This work had permitted to show that all the tested products complied with specifications in terms of dosage and purity. Variations in the composition of polysorbate 80 (PS80) have been observed but are probably too small to be responsible for the toxicity found in patients. However, we identified a difference in micelle size and release kinetics probably because of doubling concentration of ethanol in new formulation. As a result, we emphasised the importance in the case of DTX of conducting bioequivalence studies as expected in European Medicines Agency (EMA) guidance to ensure patient safety, even though these formulation changes might seem minor. Therefore, further studies are needed to explore the potential role of ethanol, PS80 and the unbound fraction of DTX in the development of enterocolitis in patients treated with DTX. • In 2010, a new docetaxel-based presentation has been introduced in the form of a single ready-to-use vial by Sanofi-Aventis. • DTX generics enter the French market with compositions of excipients different from those of the branded product. • Many fatal cases have been attributed to enterocolitis and sepsis with a digestive starting point after docetaxel use. • All the tested products complied with specifications in terms of dosage and purity. • Formulation change of DTX complex parenteral solution should have led to a biowaiver study according to the EMA guidance. [ABSTRACT FROM AUTHOR]